keyword
MENU ▼
Read by QxMD icon Read
search

Long acting antipsychotics

keyword
https://www.readbyqxmd.com/read/28291293/-adverse-effects-of-medication-and-quality-of-life-in-patients-receiving-second-generation-antipsychotics-a-comparison-of-long-acting-injectable-and-oral-therapies
#1
Demet Sağlam Aykut, Filiz Civil Arslan, Ahmet Tiryaki, Evrim Özkorumak, Serdar Karakullukçu
OBJECTIVE: Maintenance treatment with antipsychotic drugs for patients with schizophrenia is highly effective in decreasing the recurrence rate of the disease. In the current study, we aimed to compare long-acting second generation antipsychotic drug injections and oral forms of second generation antipsychotic drugs in terms of their adverse effects on quality of life. METHOD: Forty-one patients receiving second generation antipsychotic drugs and 139 patients diagnosed with schizophrenia or schizoaffective disorder were treated with oral second generation antipsychotic drugs and enrolled in the study...
2017: Türk Psikiyatri Dergisi, Turkish Journal of Psychiatry
https://www.readbyqxmd.com/read/28278537/paliperidone-long-acting-plasma-level-monitoring-and-a-new-method-of-evaluation-of-clinical-stability
#2
Massimo Carlo Mauri, Silvia Paletta, Chiara Di Pace, Alessandra Reggiori, Chiara Rovera, Alessio Fiorentini, Carlo Alfredo Altamura
The second generation long-acting antipsychotics can be a pharmacologic strategy, both in the early phase of illness and in the case of low compliance. The aim of the study was to evaluate the clinical efficacy and tolerability of one monthly injection of paliperidone palmitate (PP1M), paliperidone plasma levels (PLs), and the clinical outcome. 21 outpatients, affected by Schizophrenia or Schizoaffective Disorder, were recruited. PP1M started with 150 mg on day 1 and 100 mg on day 8. Following patients were given a dosage ranging from 50 mg to 150 mg every 28 days...
March 9, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/28260235/no-cognitive-enhancing-effect-of-glp-1-receptor-agonism-in-antipsychotic-treated-obese-patients-with-schizophrenia
#3
P L Ishøy, B Fagerlund, B V Broberg, N Bak, F K Knop, B Y Glenthøj, B H Ebdrup
OBJECTIVE: Schizophrenia is associated with profound cognitive and psychosocial impairments. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used for diabetes and obesity treatment, and animal studies have indicated cognitive-enhancing effects. In this investigator-initiated, double-blind, randomized, placebo-controlled trial, we tested non-metabolic effects of exenatide once-weekly (Bydureon™) in obese, antipsychotic-treated patients with schizohrenia spectrum disorder. METHOD: Before and after 3 months of exenatide (N = 20) or placebo (N = 20) treatment, patients were assessed with the following: Brief Assessment of Cognition in Schizophrenia (BACS), Rey-Osterreith complex figure test (REY), Short-Form Health Survey (SF-36), Personal and Social Performance Scale (PSP) and the Positive and Negative Syndrome Scale (PANSS)...
March 5, 2017: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/28258365/dosing-and-switching-strategies-for-paliperidone-palmitate-3-month-formulation-in-patients-with-schizophrenia-based-on-population-pharmacokinetic-modeling-and-simulation-and-clinical-trial-data
#4
REVIEW
Mats O Magnusson, Mahesh N Samtani, Elodie L Plan, E Niclas Jonsson, Stefaan Rossenu, An Vermeulen, Alberto Russu
Paliperidone palmitate 3-month formulation (PP3M), a long-acting injectable atypical antipsychotic, was recently approved in the US and Europe for the treatment of schizophrenia in adult patients who have already been treated with paliperidone palmitate 1-month formulation (PP1M) for ≥4 months. This article reviews the pharmacokinetic rationale for the approved dosing regimens for PP3M, dosing windows, management of missed doses and treatment discontinuation, switching to other formulations, and dosing in special populations...
March 4, 2017: CNS Drugs
https://www.readbyqxmd.com/read/28242474/antiseizure-antidepressant-and-antipsychotic-medication-prescribing-in-elderly-nursing-home-residents
#5
Sai Praneeth R Bathena, Ilo E Leppik, Andres M Kanner, Angela K Birnbaum
OBJECTIVE: The incidence of epilepsy is highest in the elderly and the prevalence of epilepsy is higher in nursing home residents than in other cohorts. Co-medications that act in the central nervous system (CNS) are frequently prescribed in this population. The objective was to identify the most commonly prescribed antiseizure drugs (ASDs) and determine the frequency of use of antipsychotic and antidepressant medications in elderly nursing home residents receiving ASDs. METHODS: Data were obtained from a pharmacy database serving 18,752 patients in Minnesota and Wisconsin nursing homes...
February 24, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/28240189/suicide-prevention-in-schizophrenia-do-long-acting-injectable-antipsychotics-lais-have-a-role
#6
Maurizio Pompili, Laura Orsolini, Dorian A Lamis, David R Goldsmith, Adele Nardella, Giulia Falcone, Valentina Corigliano, Mario Luciano, Andrea Fiorillo
Suicide risk is a major cause of death among patients with schizophrenia. Death by suicide has been reported in approximately 5% of schizophrenia patients although such figure appears an underestimation of the problem. A number of risk factors are routinely reported as associated with suicide risk among these patients, some of which are modifiable by targeted therapeutic strategies. Clozapine is the only compound that gathered evidence as an effective treatment for reducing suicide risk in schizophrenia. Long-Acting Injectable Antipsychotics (LAIs) have a range of advantages in terms of efficacy, safety and tolerability in the treatment of schizophrenia, and one area of interest is whether LAI-treatment may decrease suicidality by indirectly acting on a range of risk factors for suicide specific to schizophrenia patients...
February 23, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28236992/-evaluating-the-efficacy-of-long-acting-injectable-antipsychotics-through-clinical-trials
#7
E Fakra, J-M Azorin, R Belzeaux, M Adida, O Blin, A Kaladjian
After reminding the various phases of the development of molecules, this article will state the stages of commercialisation of treatments, underlining the FDA (Food and Drug Administration) and the EMA (European Medicine Agency) requirements. Like all the other treatments available in Europe and in the United States, the long acting injectable antipsychotics (LAI) have to prove their efficacy compared to placebo and their non-inferiority compared to a treatment of reference, usually the same molecule in the oral form...
December 2016: L'Encéphale
https://www.readbyqxmd.com/read/28225439/tachycardia-in-patients-treated-with-clozapine-versus-antipsychotic-long-acting-injections
#8
Björn M Nilsson, Oscar Edström, Leif Lindström, Petter Wernegren, Robert Bodén
Tachycardia is a known adverse effect during clozapine treatment. However, prevalence reported differs widely between studies and hitherto there are no studies comparing clozapine-treated patients with a similar control group. The present study was carried out to assess the prevalence of tachycardia in patients treated with clozapine and antipsychotic long-acting injections (LAI). Data on heart rate (HR), concomitant medication, and relevant anthropometric and laboratory measurements were collected for all clozapine-treated patients (n=174) in a defined catchment area and compared with data on patients treated with LAI (n=87)...
February 20, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28195930/treatment-duration-with-long-acting-injectable-antipsychotics-after-in-hospital-initiation-a-retrospective-cohort-study
#9
Hans Rittmannsberger, Jan Rosenleitner, Gertraud Malsiner-Walli, Regina Werl, Barbara Rittmannsberger, Kurosch Yazdi
PURPOSE: Long-acting injectable (LAI) antipsychotics are recommended especially for patients with multiple admissions and poor adherence. The empirical basis of this strategy is a matter of debate. METHODS: In a retrospective cohort study extending over 6 years, all patients admitted for inpatient treatment with a diagnosis of psychotic disorders according to International Statistical Classification of Diseases and Related Health Problems, 10th Revision (F2) were screened for treatment episodes with a new start of an LAI...
April 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28181959/indications-for-and-use-of-long-acting-injectable-antipsychotics-consideration-from-an-inpatient-setting
#10
Taishiro Kishimoto, Sohag Sanghani, Mark J Russ, Akeem N Marsh, Joshua Morris, Suparna Basu, Majnu John, John M Kane
Studies have examined the differences in sociodemographic/clinical characteristics between patients on long-acting injectable (LAI) versus oral medications. However, most studies did not focus specifically on patients for whom LAIs would clearly be indicated. We performed a chart review of patients with schizophrenia or schizoaffective disorder. Patients were categorized as having an 'indication for an LAI' or not on the basis of their adherence history. Patients for whom an LAI was indicated and prescribed on discharge were then compared with similar patients for whom an LAI was not prescribed...
February 8, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28177063/prevalence-of-and-factors-associated-with-antipsychotic-polypharmacy-in-patients-with-serious-mental-illness-findings-from-a-cross-sectional-study-in-an-upper-middle-income-country
#11
Kerryn S Armstrong, Henk Temmingh
Objective: The aim of our study was to examine the prevalence of and factors associated with antipsychotic polypharmacy (APP) among patients with serious mental illness in the current South African health care context. Methods: We collected data on patient, illness, and treatment characteristics of patients discharged on one or more antipsychotic agents from January to June 2014. We analyzed the associations of APP with demographic and clinical variables using hierarchical multivariable logistic regression, and examined prescription patterns...
February 6, 2017: Revista Brasileira de Psiquiatria
https://www.readbyqxmd.com/read/28146613/efficacy-and-safety-of-aripiprazole-once-monthly-in-the-maintenance-treatment-of-bipolar-i-disorder-a-double-blind-placebo-controlled-52-week-randomized-withdrawal-study
#12
Joseph R Calabrese, Raymond Sanchez, Na Jin, Joan Amatniek, Kevin Cox, Brian Johnson, Pamela Perry, Peter Hertel, Pedro Such, Phyllis M Salzman, Robert D McQuade, Margaretta Nyilas, William H Carson
OBJECTIVE: To evaluate efficacy, safety, and tolerability of long-acting injectable antipsychotic aripiprazole once-monthly 400 mg (AOM 400) as maintenance treatment for bipolar I disorder (BP-I). METHODS: In a double-blind, placebo-controlled, 52-week randomized withdrawal study conducted from August 2012 to April 2016, patients with a DSM-IV-TR diagnosis of BP-I currently experiencing a manic episode were stabilized sequentially on oral aripiprazole and AOM 400 and then randomized to AOM 400 or placebo...
January 31, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28145912/possible-opioid-shopping-and-its-correlates
#13
Alexander M Walker, Lisa B Weatherby, M Soledad Cepeda, Daniel Bradford, Yingli Yuan
BACKGROUND: We created an operational definition of possible opioid shopping in US commercial health insurance data and examined its correlates. METHODS: The population consisted of 264,204 treatment courses in persons with a fill for an opioid or diuretic prescription in 2012 and a second within 18 months. We examined counts of prescribers and pharmacies and the numbers of fills and overlaps for ability to discriminate courses of opioids from diuretics, which were a negative control...
January 31, 2017: Clinical Journal of Pain
https://www.readbyqxmd.com/read/28144147/neuroleptic-malignant-syndrome-an-easily-overlooked-neurologic-emergency
#14
REVIEW
Ramadhan Oruch, Ian F Pryme, Bernt A Engelsen, Anders Lund
Neuroleptic malignant syndrome is an unpredictable iatrogenic neurologic emergency condition, mainly arising as an idiosyncratic reaction to antipsychotic agent use. It is characterized by distinctive clinical features including a change in mental status, generalized rigidity, hyperpyrexia, and dysautonomia. It can be lethal if not diagnosed and treated properly. Mortality and morbidity attributed to this syndrome have recently declined markedly due to greater awareness, earlier diagnosis, and intensive care intervention...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28140680/paliperidone-for-the-treatment-of-schizophrenia-and-schizoaffective-disorders-a-drug-safety-evaluation
#15
REVIEW
M C Mauri, A Reggiori, S Paletta, C Di Pace, A C Altamura
Paliperidone, the major active metabolite of risperidone, is a second-generation antipsychotic that has been developed as an extended-release (ER) oral formulation and a long-acting injectable paliperidone palmitate (PP) formulation. Paliperidone has demonstrated efficacy in the reduction of acute schizophrenia symptoms and clinical benefits were maintained also in the long-term treatments. Paliperidone ER and PP are generally well tolerated with a predictable adverse event profile. Areas covered: Data from studies evaluating safety and tolerability in the acute and maintenance treatment of schizophrenia with paliperidone are reviewed...
March 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28139358/clozapine-and-long-acting-injectable-antipsychotic-combination-a-retrospective-one-year-mirror-image-study
#16
Lama Souaiby, Claire Gauthier, Christine Rieu, Marie-Odile Krebs, Emmanuelle Advenier-Iakovlev, Raphaël Gaillard
To evaluate efficacy and tolerability of the combination of clozapine with an antipsychotic long-acting injectable (LAI) in multi-episode patients with schizophrenia or schizoaffective disorder. Efficacy and tolerability were assessed in seventeen patients admitted to a hospital in Paris between January 2010 and June 2015, using a one-year mirror-image design. Number and length of hospitalizations significantly decreased after introducing the combination (2.1 vs 0.8, p=0.004 and 155.4days vs 26.6days, p<0...
January 27, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28119036/one-year-mirror-image-study-using-paliperidone-palmitate-for-relapse-prevention-of-schizophrenia-in-four-university-hospitals-in-canada
#17
Philippe D Vincent, Marie-France Demers, Venessa Doyon-Kemp, Josée Duchesneau, Alex Halme, Violaine Masson
BACKGROUND: Superiority of long acting injectable antipsychotics (LAI) over oral antipsychotics remains controversial and dependent on study design and inclusion criteria. Meta-analysis of 21 RCTs demonstrated no difference in their effectiveness, but meta-analysis of 25 mirror-image studies did. None of these included paliperidone palmitate (PP). METHODS: We challenged efficiency of PP in a multicentric mirror-image study. Primary outcome was total hospitalization days...
January 21, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28112539/long-acting-injectable-antipsychotics-in-children-and-adolescents
#18
Sarah Lytle, Molly McVoy, Martha Sajatovic
OBJECTIVE: While a number of articles have reviewed the use of long-acting injectable antipsychotics (LAIs) in first-episode psychosis, there has been extremely limited focus on LAIs in children and adolescents. This review of the literature evaluated use of LAIs in children and youth under the age of 18. METHODS: We conducted a comprehensive search of the PubMed, PsychINFO, CINAHL, and EMBASE databases using keywords related to LAIs, children, and psychiatric conditions, including schizophrenia, bipolar disorder, and schizoaffective disorder...
February 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28080146/perceptions-vs-evidence-therapeutic-substitutes-for-antipsychotics-in-patients-with-dementia-in-long-term-care
#19
Brianne L Olivieri-Mui, John W Devlin, Aileen Ochoa, Danielle Schenck, Becky Briesacher
OBJECTIVE: To compare differences between clinician perceptions of therapeutic substitutes for antipsychotics prescribed to patients with dementia in long term care (LTC) and published evidence. METHODS: A mixed-methods approach that included a drug information search, online survey of 55 LTC clinicians and a comprehensive literature review was used. For 41 pharmacologic antipsychotic substitute candidates identified, LTC clinicians rated the likelihood they would substitute each for patients with dementia and identified non-pharmacologic antipsychotic substitutes...
January 12, 2017: Aging & Mental Health
https://www.readbyqxmd.com/read/28055336/treatment-persistence-and-hospitalization-rates-among-patients-with-schizophrenia-a-quasi-experiment-to-evaluate-a-patient-information-program
#20
Dominic Pilon, Tony B Amos, Guillaume Germain, Marie-Hélène Lafeuille, Patrick Lefebvre, Carmela J Benson
OBJECTIVE: The effective treatment of schizophrenia requires continuous antipsychotic maintenance therapy. However, poor persistence of treatment is common among patients with schizophrenia. The objective of this study was to compare persistence and hospitalization rates among patients with schizophrenia treated with long-acting injectable (LAI) antipsychotics (i.e., paliperidone palmitate and risperidone) and enrolled in a patient information program (program cohort) with patients treated with oral antipsychotics (OAs) who were not enrolled in a patient information program (nonprogram cohort)...
January 5, 2017: Current Medical Research and Opinion
keyword
keyword
81198
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"